AKT1 and glioblastoma: Cedrol combined with the clinical drug temozolomide also exhibits synergistic suppression in glioblastoma by downregulation of AKT/mTOR signaling and chemosensitizes human leukemia K562 and CRC HT-29 cells by destabilizing plasma membrane lipid rafts 30-32.